Pierre Blanchard, Radiation Oncology Clinical Section Chief at Gustave Roussy Cancer Institute, shared a post on X:
“SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03.
- Convenient.
- Fast.
- Similar outcomes than post op brachy.
Mostly VMAT homogeneous plans.”
Pierre Blanchard highlighted findings from the STEREOPOSTOP GORTEC 2017-03 study, reporting SBRT as a viable post-resection treatment for small oral cavity cancers.
The approach offers convenience, speed, and comparable outcomes to postoperative brachytherapy, with predominantly homogeneous VMAT plans.
More posts featuring Pierre Blanchard.
